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2Abstract. Primary tumors infrequently lead to demise of cancer
patients; instead, mortality and a significant degree of morbid-
ity result from the growth of secondary tumors in distant organs
(metastasis). It is well-known that malignant tumors induce the
formation of a lymphatic and a blood vascular network around
themselves. A similar but far less studied process occurs in rela-
tion to the nervous system and is referred to as neoneurogenesis; in
fact, recent studies have demonstrated that tumors initiate their
own innervation. However, the relationship between tumor pro-
gression and the nervous system is still poorly understood. This
process is most likely regulated by a multitude of factors in the
tumor-nerve microenvironment and it is therefore important to
study the interactions between the nervous system and tumor cells
through mathematical/computational modelling: this may reveal
the most significant factors of the plethora of interacting elements
regulating neoneurogenesis. The present work is a first attempt to
model the neurobiological aspect of cancer development through
a (simple) system of differential equations. The model confirms
the experimental observations that a tumor is able to promote
nerve formation/elongation around itself, and that high levels of
nerve growth factor (NGF) and axon guidance molecules (AGMs)
are recorded in the presence of a tumor. Our results also reflect
the observation that high stress levels (represented by higher nore-
pinephrine release by sympathetic nerves) contribute to tumor de-
velopment and spread, indicating a mutually beneficial relationship
between tumor cells and neurons. The model predictions suggest
novel therapeutic strategies, aimed at blocking the stress effects on
tumor growth and dissemination.
Significance Statement. The major strength of the article re-
sides in its novelty: it constitutes a first attempt to model tumor-
induced neoneurogenesis through a set of differential equations.
The mathematical model presented is simple; nevertheless, it gives
some interesting insights of the process. In particular, it shows
that a tumor is able to induce high nerve density around itself
and cause higher levels of NGF and AGMs in the tissues. Fur-
thermore, the model confirms the empirical observation that stress
(correlated with increased release of norepinephrine) affects tumor
progression. The model suggests that cancer-induced neoneuroge-
nesis is a decisive component of tumor progression and metastasis.
In this regard, we envision that tumor-nerve interactions could
represent a therapeutic target of primary significance. It is hoped
this work will inspire further theoretical investigation into tumor
neoneurogenesis. Also, we hope that experiments will follow to
investigate proposed hypotheses such as the inverse dependence of
tumor growth and progression on stress modulators (through an
Allee effect).
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1. Introduction
A relationship between tumors and the nervous system has been sus-
pected since the second century AD with the work of the Greek physi-
cian Galen [83]. Traditionally, the nervous system has not been consid-
ered to be actively involved in the process of metastasis. However, re-
cent studies have demonstrated the presence of neurons in peritumoral
regions of several human tumors, and the number of tumor-associated
neurons has been correlated with metastases [2, 51]. The relative im-
portance of pre-existing versus newly-formed neurons to metastasis is
not understood. Although pre-existing peritumoral neurons are likely
to be sufficient for tumor spread, recruitment of neurons into the close
proximity of a tumor may increase the propensity of tumors to metasta-
size. Increased nerve density and/or presence of intratumoral neurons
should be regarded as an additional pathway for metastasis.
Significant progress has also been made in understanding the effects
of stress- and depression-mediated release of chemicals by the nervous
system on tumor cell dissemination [1,52,87]. On the one hand tumor
cells produce factors that induce the formation of a neural network,
and on the other the newly formed nerves release neurotransmitters
that affect tumor growth and migration [46, 54]. Following the termi-
nology suggested in [29], the formation of new nerve branches is herein
called neoneurogenesis, in analogy to lymphangiogenesis and (blood)
angiogenesis.
The present model aims to investigate how solid tumors induce pe-
ripheral nerve proliferation and how different types of nerves affect
tumor growth and metastasis by releasing substances such as neuro-
trasmitters. Also, we address the question of which role stress plays in
cancer progression. This model was mainly inspired by recent works
presented in [2, 54], focussing predominantly on prostate cancer [80].
The study in [2] combines in vitro experiments with autopsy analysis
of prostate cancer patients; in [54] the authors explore the effects of
the nervous system on tumor progression by altering nerve structure
and receptor activity in mice, after implanting human tumor cells in
the animals. Since the scope of our work does not include tumorige-
nesis, our model simulations start with a nonzero initial condition for
primary tumor cells, reflecting the tumor cells implanation described
in [54]. Our aim is to investigate the further evolution of these cells
and their interactions with the preexisting prostate-surrounding nerves.
The model takes major inspiration from [2], supporting the hypothesis
of a symbiosis between nerves and tumor cells.
2. Biological background
2.1. Neurons, neurotransmitters and the Autonomic Nervous
System (ANS). Neurons (or nerve cells) are the core components of
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the nervous system. The electrical signals travelling inside a neuron
are converted into signals trasmitted by certain chemicals (neurotrans-
mitters); these are then passed to another neuron across a synapse. A
neurotransmitter released by a nerve binds to a receptor on another
cell and, according to the receptor type, induces a certain action. The
collection of all the neuronal structures that together control body
functions below the level of consciousness (for instance, heart and res-
piratory rate, digestion and pupillary dilation) constitute the ANS.
The ANS is in turn made of three sub-systems; here we will focus only
on two of them: the Sympathetic Nervous System (SNS, also called
“fight or flight” system), which is responsible for quick response pro-
cesses, and the Parasympathetic Nervous System (PNS, also known
as “rest and digest” system), which governs slower responses such as
gastro-intestinal functions.
2.2. Tumor-induced neoneurogenesis. Tumors induce innervation
around themselves [30,51,65] and, in general, high levels of innervation
in tumors correlate with a poor disease outcome [2, 54]. Tumor cells
have the ability to produce substances, such as Nerve Growth Factor
(NGF), that stimulate the growth and improve the survival of nerve
cells [20, 35, 73]. NGF also promotes tumor growth [20] and inhibits
aggregation of cancer cells and thus enhances tumor invasion, although
this process is currently poorly understood [21].
Tumors also release Axon Guidance Molecules (AGMs). These molecules
were originally considered only for their role in the nervous system as
guidance cues for axons.1 In recent years, however, it was shown that
many AGMs can also influence neuronal survival and migration and
likely play an important role in cancer progression [56]. There are at
least three different families of AGMs (semaphorins, slits and netrins),
which seem to have different roles in nervous system development and
cancer progression. They are found in many different body tissues and
can regulate cell migration and apoptosis (for a review of the role of
AGMs in cancers, see [11]).
2.3. ANS effects on tumor progression. It was originally believed
that the nervous system only indirectly affected cancer development,
through perineural invasion (that is, the spread of tumors along nerve
fibers [28, 86]) and modulation of the immune function [87]. Indeed,
neurotransmitters regulate the cytotoxicity of T lymphocytes and nat-
ural killer cells [47] and induce leukocyte migration [27, 46]; the con-
sequent immunosuppression can favor tumor growth and progression,
impairing the anti-tumor response [4,87]. However, it is the migratory
1The term axon guidance denotes the process by which neurons send out axons
along a precise path in order to reach the correct targets. The tip of an axon (or
growth cone) is equipped with receptors that can sense (gradients of) chemicals,
called guidance cues, which “tell” them where to expand [19].
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effect of neurotransmitters that first suggested a direct link between
nerves and tumor progression. One theory for the spread of metas-
tases from a primary tumor to a certain organ claims that circulating
cancer cells are attracted and settle in a specific region of the body
due to the presence of factors such as chemokines or AGMs [11, 50].
This assumption is in agreement with the well-known “seed and soil”
hypothesis [33]. In particular, several studies have shown that neuro-
transmitters influence the migratory activity of cancer cells, perhaps
by inducing a phenotypic change towards a more motile phenotype via
intracellular signalling [30, 63], or simply by chemotaxis [22]. In addi-
tion, some neurotransmitters also induce tumor growth [46]. Indeed,
tumor cells express many receptors, including serpentine receptors [26]
to which neurotransmitters are ligands. Neurotransmitters can induce
several behavioral changes in tumor cells, mostly increasing their pro-
liferation and/or migration (a summary of such effects can be found
in [46]).
3. Mathematical model
We define the main domain of our study as a portion of the body
containing the prostate and its near surroundings, thus including both
the tumor and the neighboring nerves. All the variables, with the
exception of the migrating tumor cells (see below), are average concen-
trations/densities over this domain, which vary in time. We develop a
compartmental model in which an extra domain is considered for the
tumor cells which leave the main domain. A schematic of the model,
showing the variables and their interactions, can be found in Figure 1.
We distinguish between primary tumor cells (Tp) and migrating tu-
mor cells (Tm). The former are those that constitute the original tu-
mor mass; when they detach and leave the orthotopic site of the tumor
they are then designated migrating. The migrating cells are particu-
larly dangerous because they have the potential to form metastases.
Herein we do not explicitly account for the further development of the
migrated tumor cells: our variable Tm represents an indication of po-
tential metastasis formation.
NGF (G) is a neurotrophin (a kind of protein) which stimulates the
growth and enhances the survival of both Sympathetic Nerve Cells
(SNCs) and Parasympathetic Nerve Cells (PNCs). It has been found
to be secreted by tumor cells. AGMs (A) also affect the survival and
moreoever the growth of both SNCs and PNCs. In reality, there are
many kinds of AGMs, which can have completely different effects on
nerve and tumor development. Here, for simplicity, we consider them
as a single variable; taking into account the different types of AGMs
would be one step towards improving the model in future.
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Figure 1. A schematic representation of the interac-
tions among the model variables. Each variable corre-
sponds to a rounded-corners rectangular box; note that
cells are in blue while chemicals are in green. The
light red-shaded rectangular area represents the main do-
main, that is the prostate and its immediate surround-
ings. Concerning the arrows, solid blue denotes produc-
tion, dashed magenta denotes enhancement of growth
and/or survival (and axonal extension in the case of neu-
rons), dash-dotted green denotes migration enhance-
ment, dash-dotted black actual migration and dotted
red denotes apoptosis induction.
The growth of both SNCs (S) and PNCs (P ) is enhanced by NGF
and AGMs. In addition, both types of nerve cell respond to a neu-
rotransmitter called acetylcholine (Na), but only PNCs produce it;
SNCs instead secrete epinephrine (also known as adrenaline) and nore-
pinephrine (Nn, also called noradrenaline). Furthermore, norepinephrine
enhances tumor cell survival, growth and chemotaxis whereas acetyl-
choline seems to stimulate tumor cell invasion and migration [54].
3.1. Model equations. It is well documented that tumor cells natu-
rally undergo mitosis. The model accounts for this by taking constant
growth rates rT and rTm for primary and migrating tumor cells, re-
spectively. Only a fraction of primary tumor cells exhibit proliferation;
this is due to the presence of a necrotic core, that we assume to be
defined by the half inner radius of the (spherical) tumor mass [5]. This
assumption leads to the conclusion that only 7/8 of the tumor volume
(and thus primary tumor cells) proliferate. Primary tumor cells are
also exposed to the chemicals present in the domain which influence
the tumor development. Since tumor growth is enhanced by NGF [93],
we assume that the growth rate of Tp is increased in a saturating man-
ner by this factor. It has been shown that a classic logistic equation
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is often not suitable for modelling tumor growth [43]. Here we include
an Allee effect2 in the growth term to take into account the fact that
tumor cell populations tend to die out at low densities. This effect is
traditionally found in ecological literature; its inclusion in cancer mod-
elling was already suggested in [43]. The use of ecological concepts
in cancer biology and modelling is a promising development in tumor
research [68]. Here we take the Allee threshold, as defined in [43], to
be a function ϑ = ϑ(Nn) that decreases as the norepinephrine level
increases. This choice reflects the observation that norepinephrine en-
hances tumor cell survival [25, 78]. Tumor cells also die at a constant
rate dT . Interestingly, some AGMs (such as netrin-1) are also thought
to control tumor cell apoptosis [48,84]; we model this phenomenon by
adding a linear dependence on A to the death term. Finally, another
relevant aspect of tumor cell dynamics is migration. Tumor cells can
spontaneously disaggregate and move away from their original site [69].
This process is enhanced by substances produced by nerve cells and
distant organs, including AGMs [8] and acetylcholine [27, 46]. Hence,
the densities of primary and migrated tumor cells are described by the
following equations:
dTp
dt
=
7
8
Tp ·
(
rT +
G
τ1 + τ2G
)
︸ ︷︷ ︸
growth upregulated by NGF
·
(
1− Tp
kT
)
·
(
Tp
ϑ(Nn)
− 1
)
︸ ︷︷ ︸
logistic growth with Allee effect
− dT (1 + δA) · Tp︸ ︷︷ ︸
cell death
increased by AGM
− (µ0 + µ1A+ µ2Na) · Tp︸ ︷︷ ︸
migration induced by
AGM and acetylcholine
, (1)
dTm
dt
= (rTm − dT ) · Tm︸ ︷︷ ︸
natural cell
growth/death
+ (µ0 + µ1A+ µ2Na) · Tp︸ ︷︷ ︸
tumor cell migration
from the primary tumor
, (2)
where3
ϑ(Nn) =
θ1
1 + θ2Nn
.
We are interested in the effects that tumor-secreted NGF and AGMs
have on the system; here the tumor secretion rate of these two growth
factors is assumed to be constant [29, 30]. We do not include other
sources of NGF and AGMs in the main domain since these have a
negligible effect on the dynamics that we want to study here (their
effect on nerve growth in absence of tumor is implicitly included in the
logistic growth of nerve cells – see below). As chemicals, both NGF
and AGMs decay at constant rate dG and dA, respectively. They are
also internalized by both tumor [71] and nerve cells [14], which bind
2The Allee effect is an ecological term describing a correlation between the size
and the per capita growth rate of a population.
3See Appendix A.3 for the motivation of the definition of ϑ(Nn).
8 A. BIANCHI, K. SYRIGOS, AND G. LOLAS
them to their surface receptors. Here we assume that SNCs and PNCs
bind the proteins at the same rate (namely, γ2 for NGF and γ4 for
AGM). The evolution equations describing NGF and AGM dynamics
in the domain are therefore given by
dG
dt
= sGTp︸︷︷︸
production by
tumor cells
− dGG︸︷︷︸
decay
− [γ1Tp + γ2(S + P )]G︸ ︷︷ ︸
internalization by tumor
and nerve cells
, (3)
dA
dt
= sATp︸︷︷︸
production by
tumor cells
− dAA︸︷︷︸
decay
− [γ3Tp + γ4(S + P )]A︸ ︷︷ ︸
internalization by tumor
and nerve cells
. (4)
We assume that in a normal (i.e. tumor-free) setting both SNCs and
PNCs grow in a logistic manner and tend to their carrying capacities kS
and kP , which are equal to their normal equilibrium values. However,
when tumor cells are present nerve growth is enhanced by the secreted
NGF [49, 53] and AGMs [88]. This additional growth is modelled by
two saturating functions and is not subject to logistic limitation. This
is due to the fact that, given the complex shape of neurons, it is difficult
to estimate an actual maximum density. Nerve growth can also occur
as axon elongation, which does not take a significant portion of space.
Thus, the equations characterizing SNC and PNC rate of change are
dS
dt
= rS
(
1− S
kS
)
· S︸ ︷︷ ︸
logistic growth
and remodelling
+
(
G
σ1 + σ2G
+
A
σ3 + σ4A
)
· S︸ ︷︷ ︸
extra growth upregulated
by NGF and AGM
, (5)
dP
dt
= rP
(
1− P
kP
)
· P︸ ︷︷ ︸
logistic growth
and remodelling
+
(
G
pi1 + pi2G
+
A
pi3 + pi4A
)
· P︸ ︷︷ ︸
extra growth upregulated
by NGF and AGM
. (6)
Norepinephrine and acetylcholine are produced by SNCs and PNCs,
respectively, [37] at respective net rates sn and sa that we assume to
be constant. However, these two neurotransmitters are also released
by other cell types [57, 90] and we include constant sources cn, ca in
their equations. As chemicals, they decay at constant rates dn and
da, respectively. Finally, they are absorbed by tumor cells [46, 54] at
constant rates γ5 and γ6, respectively. The evolution equations for the
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neurotransmitters are then expressed by
dNn
dt
= cn︸︷︷︸
const.
source
+ snS︸︷︷︸
production
by SNCs
− dnNn︸ ︷︷ ︸
decay
− γ5TpNn︸ ︷︷ ︸
uptake by
tumor cells
, (7)
dNa
dt
= ca︸︷︷︸
const.
source
+ saP︸︷︷︸
production
by PNCs
− daNa︸ ︷︷ ︸
decay
− γ6TpNa︸ ︷︷ ︸
uptake by
tumor cells
. (8)
3.2. Parameters and initial conditions.
Parameters. Table 1 reports a list of all the parameters appearing in
the model equations. Each parameter is supplied with its estimated
value, units and source used (when possible) to assess it. References in
brackets mean that although the parameter was not directly estimated
from a dataset, its calculated value was inspired by the biological lit-
erature. When no data were found to inform a parameter value, this
was taken to be of the same order of magnitude of another reasonably
similar one. A detailed description of the estimation of each parameter
can be found in Appendix A.
Initial conditions. In order to explore model predictions in different
scenarios we will run simulations under different initial conditions on
the primary tumor cells. In particular, T 20%0 and T
10%
0 denote an initial
density of primary tumor cells corresponding to 20% and 10% of the
prostate volume, respectively (see Appendix A.2 for details). A rela-
tively high percentage is used due to the fact that data concerning the
tumor-nerve system evolution are only available for late stages of tumor
progression (as in [2]). We assume that the initial amount of tumor cells
have been implanted in healthy individuals (as done in [54], although
there human tumor cells were implanted in mice). We also assume zero
initial conditions for Tm, NGF and AGMs, because we are interested
in the growth factors produced by the tumor (see above section). All
the other values are assumed to be at their normal (tumor-free) level
when the model simulation starts.
The initial values are listed in Table 2.
4. Results
A simulation of the system of equations (1)–(8) with initial primary
tumor cell density T 20%0 (see above) is shown in Figure 2, where the
MatLab function ode45 was used to obtain the approximate solutions.
Overall, the output is in good qualitative agreement with the experi-
mental observations associated with aggressive human prostate tumor
as reported in [2]. Both sympathetic and parasympathetic nerves are,
in the presence of tumor, significantly increased in the region around
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parameter value units source
rT 4.81× 10−4 day−1 [75]
rTm 1× 10−4 day−1 estimated≈ rT
τ1 307.4 pg day (mm
3)−1 [93]
τ2 22.7 day [93]
kT 10
6 cells (mm3)−1 ( [66])
θ1 10
4 cells(mm3)−1 estimated≈1% of kT
θ2 1 mm
3pg−1 ( [12])
dT 1.27× 10−2 day−1 [18]
δ 1.29× 10−2 mm3pg−1 [10]
µ0 0.22 day
−1 [69]
µ1 9.8× 10−6 mm3pg−1day−1 [38]
µ2 2× 10−3 mm3pg−1day−1 [54]
sG 2.22× 10−3 pg cell−1day−1 [20]
dG 22.18 day
−1 [81]
γ1 5.57× 10−5 mm3cell−1day−1 [71]
γ2 5× 10−2 mm3cell−1day−1 [14]
sA 5.06× 10−3 pg cell−1day−1 [42]
dA 2.4 day
−1 [77]
γ3 10
−5 mm3cell−1day−1 estimated≈ γ4
γ4 1.47× 10−5 mm3cell−1day−1 [41]
rS 6× 10−2 day−1 [20]
kS 0.26 cells (mm
3)−1 [54]
σ1 1.29× 102 pg day (mm3)−1 [17, 74]
σ2 50 day [17,74]
σ3 7.79 pg day (mm
3)−1 [44]
σ4 0.01 day ( [44])
rP 7 day
−1 [16, 17]
kP 0.03 cells (mm
3)−1 [54]
pi1 0.33 pg cell
−1day−1 [17]
pi2 0.1 day ( [17])
pi3 1 pg day (mm
3)−1 estimated≈ σ3
pi4 0.01 day estimated≈ σ4
cn 5× 102 pg (mm3)−1day−1 ( [82])
sn 1.6 pg cells
−1day−1 [31]
dn 1.66 day
−1 [82]
γ5 2× 10−3 mm3cell−1day−1 [40]
ca 2.65× 104 pg (mm3)−1day−1 ( [61])
sa 0.73 day
−1 [67]
da 49.91 day
−1 [6]
γ6 10
−3 mm3cell−1day−1 estimated≈ γ5
Table 1. A list of all the parameters appearing in the
model equations.
the prostate, and the number of tumor cells leaving the domain are con-
stantly increasing, matching the metastases-formation report in [2,54].
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init.value value units source
Tp(0) T
20%
0 ,T
10%
0 cells/mm
3 calculated
Tm(0) 0 cells/mm
3 assumption
G(0) 0 pg/mm3 assumption
A(0) 0 pg/mm3 assumption
S(0) 0.26 cells/mm3 [54]
P (0) 0.03 cells/mm3 [54]
Nn(0) 3× 102 pg/mm3 [82]
Na(0) 5.3× 102 pg/mm3 [61]
Table 2. Values of the model variables at t = 0.
Concerning the primary tumor mass, our model predicts that after an
initial increase it reaches a nonzero equilibrium; this is in agreement
with the results of [54], which reports an increase in tumor mass within
the prostate. Also the fact that NGF and AGM levels stay high seems
realistic: NGF levels are higher in inflammation [89] and some studies
report that semaphorin 7A and netrin-1 levels are significantly elevated
in patients subject to chemotherapy and some kinds of cancers, respec-
tively [39,72]. Neurotransmitters reduce rapidly to a low nonzero level
following the sudden implantation of tumor cells. On the other hand,
our results are not in quantitative agreement with [54]; in particular,
the present model reaches an equilibrium approximately 5 days after
tumor cells implantation, whilst in [54] it takes weeks to observe such
significant changes. This may be due to the fact that the model does
not take into account other elements of the prostate environment (such
as lymphatic and blood vasculature) which compete with the nervous
system for growth factors and space, thus potentially slowing down the
dynamics. This observation is relevant, since it implies that more el-
ements surrounding the tumor site need to be considered in order to
model tumor development more precisely.
An interesting feature of the model is that a smaller initial condition
for primary tumor cells, for instance T 10%0 , gives rise to completely dif-
ferent dynamics. In this case the primary tumor goes to zero after few
days, while migrating tumor cells initially increase but then decrease
to zero (Figure 3). This behavior is in accordance with the hypothesis
that a tumor cell colony has to be bigger than a certain threshold in or-
der to proliferate [43]. Note that the migrated tumor cells could cause
tumor development in another site of the body where the conditions
are more favorable. It is notable that the model is able to reflect this
strong dependence of tumor progression on its initial conditions; this
appears to be an important feature in modern cancer research inspired
by ecological dynamics [43]. Our Allee threshold, lying between T 10%0
and T 20%0 , appears to be unrealistically high but, to the authors’ knowl-
edge, no measurement of this parameter is available for comparison. In
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Figure 2. Time-course of the model variables over a
period of 15 days for T 20%0 .
Figure 3. Primary and migrating tumor cells density
time-course for initial condition T 10%0 .
this model tumor cell survival and growth are affected only by nerves,
while in reality blood vessels also contribute to tumor maintenance by
providing oxygen and nutrients; this may (partially) account for the
high threshold.
4.1. PSA. To test the robustness of the model, we performed a pa-
rameter sensitivity analysis (PSA) by observing the effect that a 10%
increase/reduction of each parameter value has on tumor cell densities
at day 15. The model appears to be very solid in the sense that fi-
nal tumor cell densities are not greatly affected by pertrbations in the
parameter values. The only parameters that generate a change in mi-
grating tumor cells of 2% or more are reported in Figure 4. Of these,
only kT has a similar effect on primary tumor cells.
4.2. Stress and tumor progression. Many cancer patients exhibit
stress and depression, which are known to have an effect on the immune
system and consequently tumor growth [59,87]. Additionally, they may
have a direct effect as stress is associated with increased release of nore-
pinephrine by the hypothalamus and sympathetic nerves [36, 45, 64].
Here we simulate a stress condition by increasing the norepinephrine
release rate sn by sympathetic nerves. Figure 5A shows the time course
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Figure 4. Parameter sensitivity analysis. The graph
shows the effects on migrating tumor cells at day 15 after
an increase (blue) or decrease (orange) of 10% in the
parameters. Here only the parameters which induced a
percentage change of 2% or more are shown.
of primary and migrating tumor cells when sn is multiplied by 10 for
initial condition T 20%0 . The plots show that when sn is increased, the
primary tumor cell density settles quickly to a higher equilibrium, while
tumor cell migration is enhanced. This is in accordance with the exper-
imental observation that stress is related to higher cancer metastasis
and perhaps higher mortality [13, 58]. Again, our results agree quali-
tatively (but not quantitatively) with the experimental evidence.
Another interesting prediction of our model is that for some initial
conditions, such as T 10%0 , stress makes a crucial difference in tumor
development. Here, if sn is taken to be its baseline value, recall the
primary tumor tends to zero (Figure 3); in stress conditions (simulated
by multiplying sn by 10) the same initial condition leads to primary
tumor growth and a constant increase of migrating tumor cells (Figure
5B). This observation suggests that a stressful environment can affect
tumor development and therapeutic efficacy, in accordance with many
findings in the biological literature [25,87]. More experimental data are
needed to precisely quantify this effect, however this already supports
the potential for treatments targeting the sympathetic nervous system,
as discussed in [15].
Figure 5. Primary and migrating tumor cells in stress
conditions (simulated by multiplying sn by 10) for initial
conditions (A) T 20%0 and (B) T
10%
0 respectively.
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4.3. Blocking tumor acetylcholine receptors. Regarding parasym-
pathetic neural activity, it is reported in [54] that impairing the cholin-
ergic (acetylcholine) receptors on tumor cells does not significantly af-
fect tumor growth in the orthotopic site, but markedly reduces tu-
mor cell spreading and metastasis. To simulate this phenomenon, we
set µ2 = 0; that is, we consider tumor cells to be non-responsive to
acetylcholine. The output is shown in Figure 6, where we see a slower
increase in the migrating tumor cells. The model corroborates the
findings of [54] that cholinergic receptors on tumor cells are potential
clinical targets in view of limiting cancer metastasis.
Figure 6. Primary and migrating tumor cells when
acetylcholine receptors on tumor cells are blocked (p0 =
0.4); this scenario is simulated by setting µ2 = 0.
5. Discussion
This work is the first mathematical confirmation of the major role
played by the autonomic nervous sytem in promoting tumor develop-
ment and progression of prostate cancer and highlights neoneurogen-
esis as a target for cancer drug development. In the present paper
we develop a simple mathematical model for tumor neoneurogenesis
and cancer progression based on recent experimental evidence; it re-
sults that, regardless of the presence of angiogenesis and lymphan-
giogensis, tumor-induced neoneurogenesis represents a symbiotic fac-
tor for prostate tumor. This work further expands our understanding
of the process by which stress can regulate cancer aetiopathogenesis:
previous research predominantly emphasized the role of the immune
system in mediating stress effects on tumor growth and metastasis,
while our model predicts that stress can directly affect primary tumor
growth through the release of neurotransmitters. In addition, the ef-
fect of parasympatetic nerves is also captured by the model through
the acetylcholine-induced tumor migration.
This model, though quite simple, gives good insights into tumor
neoneurogenesis and offers many possibilities for expansion and im-
provement. First of all, the introduction of a spatial variable and thus
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the use of PDEs would allow a more precise description of the pro-
cesses occurring during tumor neoneurogenesis. In particular, a spa-
tial approach may be able to explain why sympathetic nerves tend to
accumulate in normal tissues and only penetrate tumor edges, while
parasympathetic nerves infiltrate tumor tissues [54]. Also, a more ac-
curate description of the spatial component could allow for a distinction
between axon elongation and nerve cell proliferation [2].
The model could be further improved by considering different vari-
ables for different kinds of AGMs, which are known to have diverse
effects on tumor cells [11]. In fact, circulating tumor cells are probably
attracted to a specific organ by chemokines and AGMs; the fate of a
new tumor cell cluster will depend on the sensitivity of the tumor cells
to the specific factors and AGMs produced in the new environment.
One could also take into account the blood and lymphatic vascula-
tures. Guidance cues for axons also have a function in (lymph)angiogenesis
[9, 24, 92]. Both angio-, lymphangio- and neoneuro-genesis promote
metastasis formation, although in different ways; for instance, blood
and lymphatic vessels offer pathways for tumor cells to disseminate,
similar to perineural invasion [28].
Another factor that could be included in the model is the immune
system, which functions as a bridge between the tumor and nervous
system and is the main cause of the indirect connections between the
two (in addition, NGF also seems to be involved in immune response
and inflammation [23,91]).
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Appendix A. Parameter estimation
A.1. Standard sizes and weights.
Domain and normal prostate sizes. We take normal prostate size to be
approximately 30mL = 3×104mm3 = Vprost [62]. Assuming a spherical
shape, this implies a radius of about 20 mm.
For our model, we consider the prostate and its surroundings. There-
fore we consider a slightly bigger sphere, with the same centre; say (for
instance) of radius 25 mm. This leads to a domain volume Vdom =
65.45× 103mm3.
Tumor cell size. In [66] the circulating tumor cells and the cultured
tumor cells in prostate cancer patiens are measured; the first ones are
found to have an average diameter of 7.97 µm, while the latters of 13.38
µm. We then take a tumor cell diameter of 10µm = 10−2mm and thus
of approximate volume Vtum cell = 5× 10−7mm3.
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Neurite diameter and nerve cell size. Take neurite diameter to be
about 1 µm [32, Table 2.1]. In [34] human Purkinje cell4 diameter
is reported to be 27 µm. We then estimate the nerve cell volume to be
approximately 10−5 mm3.
NGF molecular weight. In [70] and PhosphoSitePlus NGF molecular
weight is stated to be 26× 103 Da. However, NGF molecular weight is
estimated to be between 104 and 105 Da in [3,60]. We will then assume
the intermediate value 104 Da ≈ 1.660× 10−8 pg.
AGM molecular weight. Molecular weight of Semaphorin 4D is 96,150
Da (see product at www.abcam.com). Netrin-1 molecular weight is 75
kDa = 1.245× 10−7 pg [55].
Noradrenaline molecular weight. NE molecular weight = 169.17784
g/mol (from PubChem).
A.2. Equilibrium values.
Initial primary tumor cell densities T 20%0 , T
10%
0 . If we take an initial
density of primary umor cells corresponding to a certain percentage p0
of the prostate volume, we have that
Tp(0) =
p0 × Vprost
Vtum cell
× 1
Vdom
= p0 × 106 .
Taking p0 = 0.20 and p0 = 0.10 we have the initial conditions T
20%
0 and
T 10%0 , respectively.
Sympathetic and parasympathetic nerve density. In [54, Figure 7 A,D]
we find a quantification of sympathetic and parasympathetic (respec-
tively) neural areas in normal human prostate tissues. From the graph,
one can take a positive nerve area per field of about 1000µm2 for sympa-
thetic and 100µm2 for parasympathetic fibers, field surface = 0.15mm2.
It follows that the percentage of the area occupied by nerve fibers is
approximately 0.7% and 0.07 % for sympathetic and parasympathetic
nerves respectively. Note that here a section is 5 µm thick. However,
the staining here identify any kind of nerve fibers, and it is well known
that axon size is extremely variable depending on the type (for instance,
in [34] it is recorded a nerve diameter of 27 µm, while [76] reports a
nerve fiber layer thickness in the eye of about 100 µm). We will assume
that the nerve fibers occupy the whole thickness of the sections; thus
we conclude that sympathetic nerves account for 0.7% of the normal
prostate tissue volume and parasympathetic ones for 0.07%.
To convert these values in an actual cells/mm3 value, we recall that in
A.1 we found a domain volume of 65,450 mm3. Taking the above found
percentages of volume occupied by neural fibers, we have 458.1500 mm3
occupied by sympathetic nerves and 45.8150 mm3 by parasympathetic
4Purkinje cells: a class of nerve cells
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ones. Approximating a nerve cell a sphere of 27 µm = 27×10−3 mm di-
ameter [34], we have that 458.1500 mm3 correspond to 16,969 cells and
45.8150 mm3 to 1,697 cells. Therefore, the initial sympathetic nerve
density will be Seq = 16, 969/65, 450 ≈ 0.26 cells/mm3 and the initial
parasympathetic nerve density P eq = 1, 697/65, 450 ≈ 0.03 cells/mm3.
Noradrenaline level. In [82] the endogenous noradrenaline level in dif-
ferent rat gastrointestinal tissues was measured. Taking the approxi-
mate average value 0.3 µg/g and density of the tissue equal to water’s
(i.e. 1g=1mL), e have that this corresponds toN eqn = 0.3×103 pg/mm3.
Acetylcholine level. In [61] small intestine and kidney acetylcholine
levels are assayed in choline-deficient and normal weanling Fischer
germfree5 and open-animal-room rats; it results that acetylcholine lev-
els of the choline-supplemented germfree and open-animal-room rats
were similar in both sites. In particular, in [61, Table 1] we find that
in germfree rats acetylcholine levels in small intestine and kidneys are
0.82 µg/g and 0.24 µg/g, respectively. Taking the average of these val-
ues and considering a density equal to water’s one (1g/mL) we get the
“basal” acetylcholine level N eqa = 530 pg/mm
3.
A.3. Tp-equation.
Tumor constant growth rate rT . In [75]is reported that prostate cancer
has a very large doubling time. In particular: “Seventy-nine percent
of all patients had a doubling time of more than 24 months. Twenty
of 28 cancers thought to be clinically organ confined doubled at rates
exceeding 48 months”. We could then take rT = ln 2/48months ≈
4.81× 10−4day−1.
Tumor constant death/apoptotic rate dT . In [18] the apoptotic index
(AI) of prostatic adenocarcinoma was calculated as
AI (%) = 100× apoptotic cells/total cells .
The mean AI in 3,000 tumor nuclei was 1.27. We will therefore take
dT = 1.27× 10−2.
To compare these growth and death rates with others, we see that in [79]
it is stated that “The growth rate constants varied over a nearly 1,500-
fold range, while the regression rate constants varied over a 50-fold
range (Figure 3A). Furthermore, the regression rate constants were
consistently larger than the growth rate constants, with median values
of 10−1.7day−1 versus 10−2.5day−1, respectively.” These observations
correspond to rT ≈ 10−2.5day−1 and dT ≈ 10−1.7day−1. Now, while
dT is approximately the same computed above, rT here is bigger; this
5Note: The term “germfree” here refers to rats free from viable bacteria, par-
asites, or fungi.
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difference is explained by the fact that prostate tumor is well-known
for being particularly slow in growth.
NGF-enhanced tumor growth τ1, τ2. In [93, Figure 4A] the authors
report the dose-dependent effects of NGF on pancreatic cancer cell
growth in vitro after 48 hours. Here data are expressed as a percent-
age of increase or decrease of untreated controls. In particular, the
data in Table 3 are recorded.
NGF (ng/mL) % increase of untreated controls
6.3 approx. 130
25 approx. 180
100 approx. 210
Table 3. (Recall: 1 ng/mL = 1 pg/mm3.) Time = 48
hours = 2 days.
We then consider the NGF-dependent growth part in the Tp-equation
dTp
dt
=
(
rT +
G
τ1 + τ2G
− dT
)
· Tp
that, assuming G constant, has solution
T (t) = T0 exp
[(
rT +
G
τ1 + τ2G
− dT
)
· t
]
(9)
that for G = 0 reduces to
T (t) = T0 exp [(rT − dT ) · t] , (10)
which will correspond to the control case.
Now, from the data in Table 3 we see that if, for example, G = 6.3,
then
TG=6.3(t = 2)
TG=0(t = 2)
= exp
[
G
τ1 + τ2G
· t
]
= 1.3 .
Similarly
TG=25(t = 2)
TG=0(t = 2)
= 1.8 and
TG=100(t = 2)
TG=0(t = 2)
= 2.1 .
We thus have a system of three equations in two unknowns τ1, τ2: ln(1.3) [τ1 + 6.3 · τ2] = 2 · 6.3ln(1.8) [τ1 + 25 · τ2] = 2 · 25ln(2.1) [τ1 + 100 · τ2] = 2 · 100 (11)
From the second equation in (11) we get τ1 = 85.06 − 25 · τ2. Sub-
stituting this expression in the first equation gives τ2 = 1.98 and con-
sequently τ1 = 35.56; doing the same with the last (third) equation
in (11) gives τ2 = 2.46 and τ1 = 23.56. Taking the averages we get
τ1 = 30.74 and τ2 = 2.27. However, these values give rise to an unre-
alistically big tumor cell growth; therefore, in our simulations we will
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take these two values to be multiplied by 10, thus having τ1 = 307.4
and τ2 = 22.7. This difference is justified by the fact that the dataset
we used for our fit refers to pancreatic tumor cells, while in the paper
we focus predominantly on prostate cancer.
Maximum tumor cell density kT . The maximum tumor cell density
is given by 1mm3/Vtum cell = 2 × 106; in fact, kT corresponds to the
maximum number of tumor cells that can fit in every mm3. Now,
because of the presence of the stroma and other cells not implicitly
included in the model, we will take half of this value kT = 1 × 106
cells/mm3.
Shape of ϑ(Nn) and values of θ1, θ2. We want the function ϑ = ϑ(Nn)
to be such that ϑ(0) 6= 0 (to reflect the presence of an Allee threshold
in the presence of a strong Allee effect) and that ϑ is a decreasing
function of Nn (in fact, our hypothesis is that norepinephrine lowers the
Allee threshold, making the tumor more likely to proliferate). We thus
consider ϑ(Nn) = θ1/(1 + θ2Nn), where θ1 and θ2 are two parameters
to be determined.
For θ2, we consider [12, Figure 1], where the time course of prostate
tumor weight is shown in control mice and in mice treated with doxa-
zosin, an α1-adrenergic-antagonist (α-blocker). In the plot, we observe
that in the doxazosin-treated mice the tumor weight dropped down
from about 5 g to zero, while in control mice a tumor of weight around
2 g kept growing. Assuming that the doxazosin treatment blocked all
the adrenergic receptors on tumor cells (thus corresponding to the case
Nn = 0), and that in the control experiment the norepinephrine was at
its equilibrium value N eqn , we deduce that
• when Nn = 0 (i.e. norepinephrine does not make any effect on
tumor growth), 5 g is below the Allee threshold;
• when N = N eqn , 2 g is above the Allee threshold.
Now, since it is difficult to translate these tumor weights in tumor
cell densities (mouse prostate size and tumor cell size are probably
different from human ones), we can only use the “relative” information
contained above, that is
θ1 > 5 g
θ1
1+θ2N
eq
n
< 2 g
}
⇒ 1 + θ2N eqn >
5
2
⇒ θ2 > 5× 10−3mm
3
pg
.
We can take for instance θ2 = 1 mm
3/pg.
As pointed out in [43], no experiment has been done to measure
the “basal” Allee threshold θ1 for any kind of tumor. We will just
assume that θ1 is approximately the 1% of the carrying capacity kT ,
i.e. θ1 = 1× 104.
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AGM-induced tumor cell apoptosis δ. In [10, Table 1] we find a quan-
tification of the effect of semaphorin 3B on two different kinds of cancer
cells; these data are summarised in Table 4.
Treatment H1299 lung cancer cells MDA-MB-231 breast cancer cells
Control-CM 11× 104 16× 104
SEMA3B-CM 6× 104 5× 104
Table 4. Time = 5 days; C0 = 10
4 cells/well (six-well plates)
We will then consider the following two equations for control tumor
cells Tcontrol and for semaphorin-treated ones TSEMA:
Tcontrol(t) = T0 exp [(rT − dT ) t] and TSEMA(t) = T0 exp [(rT − dT − δA) t] ,
where A represents the concentration of axon guidance molecule (here,
semaphorin). To estimate A we consider the statement “Semiquan-
titative assay showed an average of 15–40 ng/mL SEMA3B in theC-
Mafter transfection” in the Materials and Methods section and the
fact that the medium was diluted 1:2; in this way we approximate
A ≈ 13.75 pg/mm3 (note that 1 ng/mL = 1 pg/mm3). Equipped with
all these values (recall: t = 5), we can use the data in Table 4 as follows:
H1299 cells:
TSEMA
Tcontrol
= exp (−δAt) = 6
11
, MDA-MB-231 cells:
TSEMA
Tcontrol
=
5
16
and then calculate the corresponding δ values 0.0088 and 0.0169 re-
spectively. Taking the average, we get δ ≈ 1.29× 10−2.
Spontaneous tumor cell migration µ0. In [69] about 1,400 colonies of
(rat) prostate tumor cells are observed after 8 days (see Figure 4 in
the same reference). Without knowing how big each colony is, we
will assume that 1 colony corresponds to 1 cell. Therefore, taking an
exponential decay Tp(t) = Tp(0) exp (−µ0t) for the tumor cells and
knowing that the initial cell density was Tp(0) = 2× 4× 103 cells/mL
(stated also in [69]), we can calculate µ0 = 0.22 day
−1.
AGM-induced migration µ1. In [38, Figure 3] the following % cell in-
vasion are reported for semaphorin-treated PC-3 cells6:
sema3A: ∼ 65% of control , sema3C: ∼ 135% of control
after 20 hours incubation (T0 = 10
5). The authors’ comment is: “Over-
expression of sema3A in PC-3 decreased the invasive characteristics
of PC-3 cells by 33% compared to the untransfected cells. Sema3C,
on the other hand, increased invasion by 33% compared to untrans-
fected cells”. To estimate the amount of semaphorin used in the ex-
periment, we read: “The bacterial clones transfected with sema3A
or sema3C were grown on agar plates and selected with 35 µg/mL
6PC-3 cells: androgen-independent prostate cell line.
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of kanamycin”. Therefore, in our equation for tumor cell migration
Tm(t) = T0 exp[(µ0 + µ1A)t] we will take A = 35µg/mL = 35 ×
103 pg/mm3. Finally, considering the 20-hours sema3C treatment, we
have that
T0 exp [(µ0 + µ1A)t]
T0 exp (µ0t)
= 1.33 ⇒ µ1At = ln(1.33) ⇒ µ1 = 9.8×10−6 mm
3
pg · day .
Acetylcholine-induced migration µ2. [54, Figure 3A] reports an ex vivo
quantification of tumor cell invasion of pelvic limph nodes (which drain
the prostate gland). Here data are reported both for control (saline-
treated) and carbachol-treated mice, and in the second case the in-
vading tumor cells are about the double than in the control. Notice
that since carbachol is a non-selective cholinergic (muscarinic) recep-
tor agonist, we can consider it as a substitute of acetylcholine. Then,
denoting with c the carbachol amount, we can estimate from the equa-
tion Tm(t) = T0 exp[(µ0+µ2Na)t] and [54, Figure 3A] that µ2ct = ln(2)
(since T0 exp[(µ0 + µ2c)t] ≈ T0 exp(µ0t)). To estimate the value of c,
we read in [54]: “For experiments on the PNS, 15 days after tumor cell
injection, animals received carbachol at 250 (day 0), 300 (day 1), 350
(day 2), 500 µg/kg per day (day 3) [every 12 hours, 8 divided doses]”.
First notice that the average of these amounts is 350 µ/kg over 5 weeks,
which corresponds to 10 µg/kg/day. To convert the kilos in a volume,
we take water density (1 g/mL); therefore we find the approximation
c = 10 pg/mm3/day and thus µ2 = 2 × 10−3 mm3pg−1day−1 (t = 35
days).
A.4. G-equation.
NGF decay rate dG. In [81] is stated that “Nerve growth factor (NGF)
mRNA is rapidly degraded in many non-neuronal cell types with a half-
life of between 30 and 60 min”. Hence, taking a half-life of 45 minutes,
the resulting decay rate is dG = 0.0154 min
−1 = 22.18 day−1.
NGF production by tumor cells sG. In [20, Figure 1c] it is reported that
after 24 hours, cultures of different lines of breast cancer cells expressed
approximately 0.3 ng/(mg protein) of NGF. Considering a total protein
amount of 300 pg per cell (as in HeLa cells7), we have that 1 mg = 109
pg protein corresponds to approximately 3×106 cells. Now, we have to
consider that in 24 hours the NGF also decayed; in fact the differential
equation for G in this case is
dG
dt
= sGT − dGG ⇒ G(t) =
(
G(0)− sG
dG
T
)
exp(−dGt) + sG
dG
T
7HeLa cells: an immortalised cell type used in biological research, derived from
cervical cancer cells taken from Henrietta Lacks, who eventually died of her cancer
in 1951.
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where T denotes the number of tumor cells (and G(0) = 0 in our case).
Thus, [20] tells us that G(t = 1day) = 0.3 × 103pg, T = 3 × 106cells.
Substituting these numbers in the equation (and taking the value of dG
estimated above), we determine sG = 2.22× 10−3 pg · cells−1 · day−1.
NGF internalization rate by tumor cells γ1. In [71, Table 1] it is re-
ported the internalization of 125I-NGF after 1 hour or 24 hours incu-
bation of different cell lines with 10 ng/mL. For SKBr5 breast carci-
noma cells, we find that 33,560 molecules/cell were internalised af-
ter 24 hours incubation. Considering a NGF molecular weight of
1.660 × 10−8 pg and knowing that the cells were seeded at density
2× 107 cells/10 mL = 2× 103 cells/mm3, we can wite down the equal-
ity
γ1×
(
2× 103 cells
mm3
)
×
(
10
pg
mm3
)
= 33.56×103×1.660×10−8 pg
mm3
×2×103 cells 1
day
,
which leads to γ1 = 5.57× 10−5 mm3cells−1day−1.
NGF internalization rate by nerve cells γ2. We can estimate the rate of
NGF internalization by cultured neurons using the data in [14, Figure
1]. The plot reports the pg of 125I-NGF binding to rat sympathetic
neurons versus different amounts of free NGF. It is also stated that the
neurons were incubated for 140 minutes with the NGF at a density of
approximately 1,000 neurons/dish in 35-mm culture dishes.
Therefore, if we have a density of free NGF equal to G0, the cor-
responding value on the y-axis of [14, Figure 1] corresponds to G(t =
140min) = G0 exp(−γ2St). Then, converting these data into our units,
we can use the MatLab functions nlinfit and nlparci to get an es-
timate for γ2 and its 95% confidence interval respectively. The plot of
the fit is reported in Figure 7 and the output is:
>> claude.ngf = [5 20 40 60]
>> claude.binding = [4.98 19.95 39.90 59.865]
>> NGFinternFIT(claude)
Estimated gamma2 value = 0.048342
ci for gamma2 = 0.0422 0.0545
A.5. A-equation. A large class of secreted or membrane bound axon
guidance molecules are semaphorins and more specifically the so called
class-3 semaphorins, that include seven family members. Class 3 semaphorins
are the only secreted vertebrate semaphorins. In a recent work, the au-
thors of [7] highlighted that Semaphorin 3E is not only overexpressed
in prostate cancer but also affects adhesion and motility of prostate
cancer cells. They also demonstrated that all the prostate cancer cell
lines that have been tested produce both the unprocessed (87kDa) and
processed (61kDa) form of Sema3E. However the effect of tumor and
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Figure 7. Plotting the data from [14] (red circles) to-
gether with the function G(t) = G0 exp(−γ2St) (blue
line) fitted to the data with the MatLab function
nlinfit.
stromal secreted semaphorins on tumor functionalities such as migra-
tion, apoptosis, growth and invasion is likely to depend on which co-
receptors are expressed. Namely, sema3E act as a chemoattractant fro
neurons expressing NRP1 receptors, that have been found to have a
high expression on prostate tumors.
AGM tumor secretion rate sA. In [42] the concentration of secreted
sema3s in conditioned medium is estimated for specific tumor cell lines.
As it can be deduced by [42, Figure 2] the relative concentrations of
class-3 semaphorins secreted into the medium of tumor cell lines were
1000 and 500 sema3-expression per cell. Tumor cells were incubated
for 48 hours = 2 days. Take an average of the aforementioned values,
we deduce that the expression of sema3 pre-cell per-day is 350. Taking
the molecular weight of unprocessed sema3 to be 87kDa (as described
at the beginning of this section A.5), we estimate that the secretion
rate is: sA = 350 × 87000 × 1.66 × 10−12pg cell−1day−1, thus sA ≈
5.055× 10−5pg cell−1day−1. However, in [42] it is highlighted that the
aforementioned expressed semaphorins did not affect the proliferation
rate or the survival of the different semaphorin tumor producing cells.
In this regard, we expect that during tumor driven neo-neurogenesis
the expressed tumor secreted sema3E are 100 or 1000 higher then the
estimated value, in other words we take sA = 5.06×10−3pg cell−1day−1.
AGM decay rate dA. In [77, Supplementary Tables 1 and 2] we find the
mRNA half-life of different kinds of semaphorins. We take an average
decay rate of 0.1 h−1 = 2.4 day−1.
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In [55] we read: “Currently, little is known about the half-life of
netrin-1 protein in any context”.
AGM internalization by nerve cells γ4. In [41, Figure 4] it is studied the
binding of netrin(VI•V)-Fc to DCC-expressing cells (spinal commis-
sural axons). Here the c.p.m. are reported for different concentrations
of netrin. Assuming the every binding corresponds to 1 molecule, and
taking the netrin molecular weight 1.245×10−7 pg, we can calculate the
decrease of free netrin, that in our system is represented by the variable
A and in this case is modelled by the equation A(t) = A0 exp(−γ4St).
Then, having S = 2.5 × 105 cells/24-well = 71.43 cells/mm3 (24-well
→ 3.5 mL) and t = 1 minute = 6.9444× 10−4 days, we can fit this as a
function of A0, as in [41, Figure 4]. The MatLab functions nlinfit and
nlparci give the following γ4 estimate and 95% confidence interval:
>> keino.netrin = [0 1 2 5 10].*10^3
>> keino.binding = [0.5 1.5 3.5 4.5 4.5].*10^4
>> AGMinternFIT(keino)
Estimated gamma4 value = 1.4673e-005
ci for gamma4 = 1.0e-004 * [ 0.0462 0.2472 ]
The plot of this fitting is reported in Figure 8.
Figure 8. Plotting the data from [41] (red circles)
together with the function A(A0) = A0 exp(−γ4St)
(blue line) fitted to the data with the MatLab function
nlinfit.
A.6. S-equation.
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Basal SNC growth rate rS. In [20, Table 1] we find that 4.4% control
sympathetic neurons cultured for 48 hours showed a neurite length of
29 mm. The initial cell density was 2 × 103 cells/well that, assuming
a well volume of 100 mL, correspond to S0 = 2 × 10−2 cells/mm3;
moreover, taking a neurite diameter of 1 µm, we have that 29 mm
neurite correspond o approximately 2.9 cells (recalling that we consider
a nerve cell volume of about 10−5mm3).
From [20]: “Cell culture plates (96-well) were prepared by incubating
each well with 100 mL of 0.1mg/mL poly-L-lysin in sterile distilled
water [...] Approximately 2× 103 cells, prepared from embryonic day-
12 chick paravertebral sympathetic ganglia, were added to each well in
100 mL of a 1:1 mixture of [...] medium”.
Hence, we conclude that after 2 days of experiment there were
S(t = 2) = S0+0.044×S0×2.9 cells ⇒ S(t = 2) = 2.2552×10−2cells/mm3 = S0 exp (2 · rS) ,
from which we can calculate rS = 0.06 day
−1.
SNC carrying capacity kS. In absence of tumor, we know that the SNC
equilibrium value is Seq = 0.26 cells/mm3 (see section A.2). We then
take kS = S
eq.
NGF-enhanced SNC growth σ1, σ2. In [74, Table 1] the effects of NGF
treatment on superior cervical ganglion cell dendritic morphology are
reported; they are summarised here in Table 5.
Treatment Animal size Total dendritic length (µm)
Control 23.5 g 721
NGF 23.5 g 929
Table 5. Mouse 2.5S NGF was administered daily to
mice by subcutaneous injection in a dosage of 5 mg/kg.
The animals were treated for 2 weeks.
Now, if we take a dendritic diameter of 1 µm and a nerve cell volume
of 10−5 mm3, we have that 1 µm dendrite corresponds to about 10−4
cells. Therefore, we can “convert” the previous dendritic lengths in
cells (at least roughly). For the NGF treatment, we know that it was 5
mg/kg/day for 2 weeks. If a mouse was 23.5 g, we have that each ani-
mal received 117.50×106 pg/day. Being NGF injected subcutaneously,
we assume that only 1% of the dosage actually contributed to the ex-
periment (the rest being dispersed by body fluids). Additionally, we
estimate a total mouse volume of 28.57× 103 mm3 (knowing that mice
blood volume is about 2 mL and it constitutes 7-8% of their total vol-
ume [85]) and thus we have a daily NGF supply of 41.13 pg/mm3/day.
Now, to calculate the effective NGF present, we have to take into ac-
count its decay. We know that NGF decay rate is dG = 22.18 day
−1
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(see A.4); if we define the constant supply s = 41.13 pg (mm3)−1day−1,
we have that the evolution equation for G in this setting is
dG
dt
= s− dGG =⇒ G(t) = G0edGt − s
dG
e−dGt +
s
dG
.
Then, taking G0 = 0, we have that at t = 1 day the amount of NGF
is approximately 1.85 pg/mm3. For the two-week experiment, we will
then assume G to be 1.85 × 14 = 25.96 pg/mm3. Then, back to the
S-equation: we recall that the bit in which we are now interested is
dS
dt
=
(
rS +
G
σ1 + σ2G
)
S
G const
=⇒ S(t) = S0 exp
[(
rS +
G
σ1 + σ2G
)
t
]
we have that at 2 weeks = 14 days
SNGF
Scontrol
= exp
(
G
σ1 + σ2G
× 14
)
=
929
721
= 1.29 .
From this equation (recall: G = 25.96) we derive σ1 = 25.96×(54.9791−
σ2). Consequently, we have that it must be σ2 < 54.9791 in order to
have σ1 > 0.
We can derive a second equation for σ1 and σ2 from the experimen-
tal results reported in [17]. In fact, [17, Table 1] lists the maximal
effects on neurite lengths of various additions to the culture medium.
In particular, the mean total neurite length per neuron after different
treatments divided by the corresponding value of the untreated control
is reported. For sympathetic neurons exposed for 2 hours to 1 ng/mL
NGF, the relative length is 2.47; this observation allows us to write the
following equality:
exp
(
G
σ1 + σ2G
× 0.0833
)
= 2.47 =⇒ σ2 = 57.1782 ,
the latter obtained after substituting the expression for σ1 found pre-
viously (note that 2 hours = 0.0833 days). Notice that although σ2
is bigger than 54.9791, the difference is small (less than one order of
magnitude). This is probably due to the fact that the two references
used to estimate σ1, σ2 deal with completely different experimental set-
tings (for example, the experiment done in [74] is in vivo while [17] is
in vitro). Therefore it seems justified to take for instance σ2 = 50 days
and consequently σ1 ≈ 129 pg day (mm3)−1.
AGM-enhanced SNC growth σ3, σ4. In [44, Figure 1A(ii) and 2A] the
synapse density after 0.5, 1, 2 and 4 hours of Sema4D treatment is re-
ported as % of control. In particular, it is reported that after 0.5 hours
= 0.0208 days = t1 of 1nM-Sema4D-treatment GABAergic synapse for-
mation in rodent hippocampus was about 130% of control, and after 1
hour = 0.0417 days = t2 it was approximately 150% of control. Now,
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recalling the “growth bit” of the S-equation
dS
dt
=
(
rS +
A
σ3 + σ4A
)
S
A const
=⇒ S(t) = S0 exp
[(
rS +
A
σ3 + σ4A
)
t
]
,
we have from the previous datapoints that
exp
(
At1
σ3 + σ4A
)
= 1.3 and exp
(
At2
σ3 + σ4A
)
= 1.5
(since the control corresponds to the S(t) where A = 0). Note that
taking molecular weight of 96,150 Da for A, we have that A = 1 nM =
96.117 pg/mm3. Finally, considering the average of the two expressions
above we can estimate
σ3 + σ4A ≈ 1
2
(
At1
ln(1.3)
+
At2
ln(1.5)
)
⇒ σ3 ≈ 8.75− 96.12× σ4 .
Note that we must choose σ4 < 0.0911 in order to have σ3 > 0. Taking
for instance σ4 = 0.01, we have consequently also σ3 = 7.79.
A.7. P -equation.
Basal PNC growth rate rP . In [16, Table I] it is reported that the
mean total neurite legth/neuron after 23/4 hours in conditioned medium
was 408 µm, while in the unconditioned medium it was 118 µm (they
study ciliary ganglia, which are parasympathetic ganglia located in the
posterior orbit). Taking the latter as the initial value P0, we have from
the equation describing PNC dynamics in this context
P (t = 23/4h = 0.1146day) = P0 exp (rP × t)
⇒ 0.1146× rP = ln
(
408
118
)
⇒ rP = 10.83 day−1 .
In the same reference we find another useful dataset in [16, Table II].
Here it is stated that the mean elongation rate of 14 neurites (chosen to
be at east 15 µm long) without any medium change was 22 µm/hour.
Converting these lengths into cell numbers (using the calculations done
in A.1) and keeping in mind that 1 hour = 0.0417 days, we calculate
the growth rate “per cell” rP as 22/14×15× 1/0.0417 = 2.51 day−1.
Another way to determine rP could be to use the data in [17, Table
1]. Here the authors measure the maximal effect on ciliary (parasym-
pathetic) and sympathetic neurite growth in various culture media
after 2 hours. Considering the data regarding the “standard” con-
ditioned medium, we have that the relative neurite length for cil-
iary neurons was 3.42, and for sympathetic neurons 1.81. Then, as-
suming an exponential growth for both cell cultures, we have that
P0 exp(rP t)/S0 exp(rSt) = 3.42/1.81; furthermore, taking P0 = S0 and
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t = 2h = 0.0833day, we have that rP − rS = 7.63 day−1. Now, re-
calling our previous estimate for rS (rS = 0.06, see A.6), we have
rP = 7.70 day
−1.
It is encouraging to see that all these three values are of the same
order of magnitude. To choose an estimate for rP , we take their average
7 day−1.
PNC carrying capacity kP . In absence of tumor, we know that the PNC
equilibrium value is P eq = 0.026 cells/mm3 (see section A.2). We then
take kP = P
eq.
NGF-enhanced PNC growth pi1, pi2. [17] investigated (in vitro) the effect
of NGF on promoting the parasympathetic ciliary ganglion outgrowth.
Their calculations were used to calculate the mean total length of neu-
rites per neuron. Their calculations were based on data from neu-
rons that had at least one neurite greater then 15 µm in length (≈
about the diameter of the neuronal soma). In this regard when they
added NGF to dissociate ciliary ganglion neurons, resulted in a 2-fold
increase in neurite length over untreated, control cultures.They esti-
mated the mean total neurite length per neuron for control cultures to
be 79 ± 19µm. Parasympathetic ganglion neurons were exposed to a
concentration of 10ng/mL = 10×10
3
103
pg
mm3 per h. Just two hours after
addition of NGF the ratio PNGF
Pcontrol
≈ 2.08± 0.12.
Recalling the given P equation:
dP
dt
=
(
rP +
G
pi1 + pi2G
)
S
G const
=⇒ P (t) = P0 exp
[(
rP +
G
pi1 + pi2G
)
t
]
;
so after two hours we have
PNGF
Pcontrol
= exp
(
G
pi1 + pi2G
× 2
24
)
= 2.08 .
Taking into account that 2 hours ≈ 2
24
day = 0.083day we deduce that
10
pi1 + pi2 × 10 × 0.083 = ln 2.08
and therefore pi1 = 1.33 − 10 × pi2. Note that it must be pi2 < 0.13
in order to have pi1 > 0. We can take for example pi2 = 0.1 and thus
pi1 = 0.33.
A.8. Nn-equation.
Noradrenaline production by SNC sn. Regarding the norepinephrine
release rate, [31] estimated the apparent norepinephrine release rate at
rest to be 0.54±0.20µg/(m2min) = 777.60 pg/mm2×day. Note that 90%
of this release rate is due to the sympathetic nerves. To convert the
mm2 in cells, we assume once again a nerve cell radius r = 13.5µm =
13.5× 10−3m (see A.1); the surface area is given by 4pir2 = 4pi(13.5×
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10−3)2 ≈ 2.29 × 10−3mm2, thus we deduce that in 1 mm2 there are
1/(2.29× 10−3) = 436.7 nerve cells. The noradrenaline secretion rate
is then given by sn = 0.9× 777.60/436.7 ≈ 1.6 pg cells−1day−1.
Noradrenaline decay rate dn. In [82] the noradrenaline half-life is re-
ported to be about 10 hours (although this value is different in different
tissues). This leads to a decay rate dn = 1.66 day
−1.
Noradrenaline uptake rate (by tumor cells) γ5. In [40, Figure 4A] we
find one set of measurements of NE uptake by human pheochromocy-
toma8 cells. Recalling the molecular weight of NE found in A.1 and
assuming a culture volume of 1 mL (it is not better specified in the
paper), we can convert the datapoints in [40, Figure 4A] into our units
and fit the function N(t) = N0 − N0 exp(−γ5Tt) to them; note that
T represents the tumor cells, and that the value of this function at
each time t is measured as the initial substrate concentration minus
the uptaken NE. Using the MatLab function nlinfit to fit the data
gives:
>> jaques.substr = 169.18.*[1 2 3 4 5]
>> jaques.uptake = 169.18*10^(-3).*[15 32 45 53 65]
>> NEinternFIT(jaques)
Estimated gamma5 value = 0.0019926
ci for gamma5 = 0.0018 0.0022
The plot of the fit is reported in Figure 9.
Noradrenaline constant source cn. We fund in A.2 that in normal con-
ditions (i.e. in the absence of a tumor) the level of noradrenaline is
N eqn = 300 pg/mm
3. We can then calculate cn from the equilibrium
equation
cn + snS
eq − dnN eqn = 0 ⇒ cn ≈ 500
pg
mm3day
,
where Seq and P eq were also found in A.2 and sn,dn were estimated
above.
A.9. Na-equation.
Acetylcholine release rate sa. In [67] the output of acetylcholine from
the plexus of the guinea-pig ileum longitudinal strip is used to study
the mechanism of acetylcholine release. The resting output is reason-
ably constant for a given preparation for long periods; the mean value
for eighty-four experiments was about 51 ng/g·min. The evoked out-
put, however, usually changes as stimulation is prolonged, in a manner
varying with the stimulation used. Assuming a nerve cell volume of
10−5 mm3 (see A.1) and of density equal to water’s one (1g/mL), we
8A pheochromocytoma is a neuroendocrine tumor of the medulla of the adrenal
glands; it secretes high amounts of catecholamines, mostly norepinephrine, plus
epinephrine to a lesser extent.
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Figure 9. Plotting the data from [40] (red circles) to-
gether with the function N(t) = N0 − N0 exp(−γ5Tt)
(blue line) fitted to the data with the MatLab function
nlinfit.
have that 1 g of parasympathetic nerves corresponds to approximately
108 cells. Therefore, we estimate the acetylcholine production rate as
sa = 0.73 pg/cell day.
Acetylcholine decay rate da. In [6] the authors studied the influence
of the stimulus interval and the effect of Mn ions on facilitation9 of
acetylcholine (ACh) release from parasympathetic nerve terminals in
quiscent guinea-pig auricles. Here we also find that when conditioning
trains of stimuli were applied, a second much longer lasting component
of facilitation was found (t1/2 ≈ 4 s). Also, the decay to the control
level displays a half time of about 20 min and can also be accelerated
by frequent stimulation of the parasympathetic nerve fibres. In this
regard we can estimate da = 49.91day
−1 (taking 20 min).
Acetylcholine constant source ca. In A.2 we estimated that in normal
conditions (i.e. in the absence of a tumor) the acetylcholine level in
the tissue is N eqa = 530 pg/mm
3. We can then calculate ca from the
equilibrium equation
ca + saP
eq − daN eqa = 0 ⇒ ca ≈ 26.5× 103
pg
mm3day
,
where Seq and P eq were also found in A.2 and sa,da were estimated
above.
9Note: Here the term facilitation denotes an increase in transmitter release
during repetitive nerve excitation
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